The Manufacturers Life Insurance Company Sells 4,881 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

The Manufacturers Life Insurance Company reduced its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 1.8% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 260,355 shares of the biopharmaceutical company’s stock after selling 4,881 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Halozyme Therapeutics were worth $14,903,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in HALO. Congress Asset Management Co. lifted its holdings in shares of Halozyme Therapeutics by 446.5% during the third quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock worth $139,298,000 after buying an additional 1,988,238 shares in the last quarter. Handelsbanken Fonder AB raised its stake in Halozyme Therapeutics by 76.9% in the 3rd quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock worth $112,715,000 after purchasing an additional 856,200 shares in the last quarter. Boston Trust Walden Corp acquired a new stake in Halozyme Therapeutics in the 2nd quarter worth about $23,211,000. Dimensional Fund Advisors LP grew its position in shares of Halozyme Therapeutics by 12.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock worth $99,363,000 after purchasing an additional 209,530 shares in the last quarter. Finally, Federated Hermes Inc. grew its position in shares of Halozyme Therapeutics by 37.8% during the 2nd quarter. Federated Hermes Inc. now owns 696,131 shares of the biopharmaceutical company’s stock worth $36,449,000 after purchasing an additional 191,030 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $53.26, for a total value of $532,600.00. Following the completion of the transaction, the senior vice president now directly owns 173,756 shares in the company, valued at approximately $9,254,244.56. This trade represents a 5.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last quarter, insiders have sold 60,000 shares of company stock valued at $3,425,000. 2.40% of the stock is currently owned by insiders.

Halozyme Therapeutics Trading Down 0.6 %

Shares of Halozyme Therapeutics stock opened at $48.20 on Monday. The firm has a market capitalization of $6.13 billion, a PE ratio of 15.96, a price-to-earnings-growth ratio of 0.44 and a beta of 1.29. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. The firm’s 50 day moving average is $53.28 and its 200 day moving average is $53.79. Halozyme Therapeutics, Inc. has a 1 year low of $33.15 and a 1 year high of $65.53.

Analyst Ratings Changes

Several equities research analysts recently issued reports on HALO shares. Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Benchmark reissued a “buy” rating and set a $60.00 target price on shares of Halozyme Therapeutics in a report on Thursday, August 8th. Morgan Stanley boosted their price target on Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Piper Sandler raised their target price on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the company a “neutral” rating in a report on Monday, November 4th. Finally, JMP Securities upped their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $61.11.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.